Eisai Co Ltd (Eisai) carries out the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) and prescription drugs and therapeutic agents.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Eisai has been actively involved in various R&D initiatives to develop innovative therapeutics for Alzheimer's disease (AD) and broader dementia. The company's open innovation ecosystem aims to create comprehensive solutions for prediction, prevention, treatment, and care in dementia through pharmacotherapeutics and non-pharmacotherapeutics. Eisai is seeking proposals from scientists with unique ideas and research programs in areas such as modulation of the Neuro-Glia-Vascular Unit in the brain, nerve regeneration without transplantation, brain- or cell-specific delivery systems, novel fluid biomarkers for neurodegenerative disease, and brain stimulation techniques to enhance synaptic connections. The company has formed partnerships with multiple universities and companies such as University College London, Keio University, Washington University in St. Louis, NEURii, BioArctic AB, and Sysmex Corporation for collaborative research and development. The company incurred research and development expenses of JPY154,316 million in FY2025.